Shannon Morris, M.D., Ph.D.
About Shannon Morris, M.D., Ph.D.
Shannon Morris, M.D., Ph.D., serves as the Chief Medical Officer with extensive experience in oncology and molecular virology, previously holding significant roles at Istari Oncology, G1 Therapeutics, and MedImmune.
Chief Medical Officer Shannon Morris, M.D., Ph.D.
Shannon Morris, M.D., Ph.D., currently serves as the Chief Medical Officer. With extensive experience in oncology and clinical development, she provides leadership and strategic oversight for clinical programs. Her role involves spearheading clinical research initiatives, optimizing therapeutic strategies, and contributing to the advancement of medical treatments. Dr. Morris's leadership ensures that clinical operations align with the highest standards of medical practice.
Shannon Morris' Education and Expertise
Shannon Morris holds a B.S. in biological sciences from Stanford University. She pursued further education at Case Western Reserve University, earning both an M.D. and a Ph.D. in molecular virology. Her educational background laid a strong foundation for her specialization in oncology. Post-graduation, Dr. Morris completed her internal medicine residency and oncology fellowship at the University of North Carolina, shaping her clinical expertise and research proficiency.
Background of Shannon Morris
Shannon Morris has a diverse background in clinical development and oncology. She has held pivotal roles at various organizations, including Istari Oncology where she served as Vice President, Head of Clinical Development. Prior to that, she was the Vice President of Clinical Development at G1 Therapeutics. Her career path reflects a commitment to advancing cancer treatments through innovative clinical research and development.
Shannon Morris' Achievements in Clinical Development
During her tenure at MedImmune, Shannon Morris supported the successful biologics license application (BLA) for Imfinzi, showcasing her expertise in regulatory approvals and clinical strategy. She has also focused on the early phase development of small molecule inhibitors of AKT, PI3K, and MEK at GlaxoSmithKline. These roles highlight her contributions to early-stage drug development and her capability in steering complex clinical trials.
Shannon Morris' Affiliations and Appointments
Shannon Morris maintains an adjunct appointment at the University of North Carolina. In this role, she is involved in the clinical care of patients with breast and gastrointestinal cancers. Her ongoing academic engagement complements her professional endeavors, allowing her to stay connected with the latest medical research and clinical practices.